Sunday, June 30, 2013

Afflicted: Lyme disease in Vermont

Here's a video about Lyme disease in Vermont. It was published in the Poughkeepsie Journal. Two Vermont farmers with Lyme diagnoses are interviewed.

Friday, June 28, 2013

How Quickly Can a Tick Infect You?

Clinical evidence for rapid transmission of Lyme disease following a tickbite

Eleanor D. Hynote, Phyllis C. Mervine, Raphael B. Stricker
Diagnostic Microbiology and Infectious Disease, online
before print, November 20, 2011.

Lyme disease transmission to humans by Ixodes ticks is
thought to require at least 36–48 h of tick attachment. We
describe 3 cases in which transmission of Borrelia
burgdorferi, the spirochetal agent of Lyme disease, appears
to have occurred in less than 24 h based on the degree of
tick engorgement, clinical signs of acute infection, and
immunologic evidence of acute Lyme disease.

Health care providers and individuals exposed to ticks
should be aware that transmission of Lyme disease may occur
more rapidly than animal models suggest. A diagnosis of Lyme
disease should not be ruled out based on a short tick
attachment time in a subject with clinical evidence of B.
burgdorferi infection.

The rest of the study can be found here:

Petition: Calling for a Congressional investigation of the CDC, IDSA and ALDF

Letter to the Editor, The Lancet Infectious Diseases Published May 2012

Thursday, June 27, 2013

Who says Lyme disease persists after antibiotic therapy?

This amazing library of information about Lyme disease was just brought to my attention this evening. Check it out. This is just one example of what is on the site:

Persistence File:
77 peer-reviewed studies showing that Lyme disease can persist or relapse despite antibiotic therapy. 18 pages. Last modified: May 2012

Blumenthal Chairs Senate Hearing In State On Lyme Disease Prevention

Blumenthal Chairs Senate Hearing In State On Lyme Disease Prevention, Hears From Senate Colleague, Patients And Experts

Read the testimony from our panel of patients and experts here.

(Hartford, Conn.) – Today, Senator Richard Blumenthal (D-Conn.) chaired a U.S. Senate field hearing on the federal response to Lyme disease in his capacity as a member of the U.S. Senate Committee on Health, Education, Labor, and Pensions. This hearing, which was widely attended by patients, researchers, and health care providers from the northeast, explored next steps the federal government must take to combat Lyme disease, and how the patient perspective can assist in this effort.

Today’s field hearing emphasized the importance of putting politics aside and bringing all stakeholders together in the fight against Lyme,” said Blumenthal who has been a leader in the fight against Lyme disease throughout his career and a strong advocate for patients with the disease. He introduced the bipartisan Lyme and Tick-Borne Disease Prevention, Education, and Research Act (S. 1381) during his first year as a U.S. Senator, legislation that would raise awareness about Lyme disease, support diagnostic research, and provide more resources to fight the illness

Blumenthal added, “Lyme disease is a pervasive and pernicious public health disaster that is aggressively spreading to other regions of the country. This hearing further underscored the urgent need for a strong national initiative to combat Lyme disease. Today there was strong consensus that the nation must improve reporting of Lyme cases and develop better diagnostic tools. Inadequate diagnosis and reporting cause devastating damage to countless individuals every day. The disease has reached epidemic proportions, and a national advisory body that gives patients a voice and a seat at the table with policymakers, scientists, researchers and others is imperative to better prevent and treat this disease. I will continue to fight for a bill that will establish such a body, along with other reforms.”  

The hearing included three panels. Senator Kirsten Gillibrand (D-N.Y.) – a powerful voice in the fight against Lyme disease –testified on the first panel. Senator Gillibrand provided her perspective on the actions that are needed to fight Lyme disease as a legislator representing the state of New York – a state that has one of the highest incidences of Lyme disease in the country.  

“Summer is in full swing, and there is nothing better than enjoying the weather outside with friends and family. But the joy of a summer day can too easily turn deadly from Lyme disease that's taken too many of our loved ones,” said Gillibrand. “It's time once and for all to take the right steps to prevent this horrible disease. We need to do more than check our kids for ticks when they come in from playing. We must invest in better research, educate families on the risks and emphasize prevention, and improve treatment strategies. This bill would develop better tools for diagnosing and reporting Lyme disease, and ensure doctors are better equipped to diagnose and treat those who become infected.”

Three patients testified on the second panel – Mark Hopwood of Trumbull, Dwight Harris of Burlington, and Katy Reid of Ridgefield. They discussed their experience as Lyme disease patients and the need for a patient voice in the prevention, research, and treatment discussion. 

Three Lyme disease experts testified on the third panel – Dr. Kirby Stafford, a medical-veterinary entomologist with the Connecticut Agricultural Experiment Station who is an expert on controlling the blacklegged tick that transmit the agents of Lyme disease, Dr. Amiram Katz, an assistant clinical professor of neurology at the Yale University School of Medicine who specializes in the treatment of Lyme disease, and Dr. Joann Petrini, the Director of Clinical Outcomes and Health Services Research in the Department of Medical Education and Research at Western Connecticut Health Network and an integral member of the Lyme Disease Registry Team.

Dr. Stafford spoke about the prevalence of tick-borne illness and the need for better prevention efforts. Dr. Katz spoke about different clinical manifestations of Lyme, the challenges posed by long-term Lyme symptoms, and the need to remain open-minded in considering how to treat the disease. And finally, Dr. Petrini spoke about ongoing research efforts and the need for patient-centered, comprehensive investigations into Lyme disease.

See the source, other links, and contact information:

Dynamics of connective-tissue localization during chronic Borrelia burgdorferi infection

Laboratory Investigation , (24 June 2013) | doi:10.1038/labinvest.2013.81

Dynamics of connective-tissue localization during chronic Borrelia burgdorferi infection
Denise M Imai, Sunlian Feng, Emir Hodzic and Stephen W Barthold

The etiologic agent of Lyme disease, Borrelia burgdorferi, localizes preferentially in the extracellular matrix during persistence. In chronically infected laboratory mice, there is a direct association between B. burgdorferi and the proteoglycan decorin, which suggests that decorin has a role in defining protective niches for persistent spirochetes. In this study, the tissue colocalization of B. burgdorferi with decorin and the dynamics of borrelial decorin tropism were evaluated during chronic infection. Spirochetes were found to colocalize absolutely with decorin, but not collagen I in chronically infected immunocompetent C3H mice. Passive immunization of infected C3H-scid mice with B. burgdorferi-specific immune serum resulted in the localization of spirochetes in decorin-rich microenvironments, with clearance of spirochetes from decorin-poor microenvironments. In passively immunized C3H-scid mice, tissue spirochete burdens were initially reduced, but increased over time as the B. burgdorferi-specific antibody levels waned. Concurrent repopulation of the previously cleared decorin-poor microenvironments was observed with the rising tissue spirochete burden and declining antibody titer. These findings indicate that the specificity of B. burgdorferi tissue localization during chronic infection is determined by decorin, driven by the borrelia-specific antibody response, and fluctuates with the antibody response.

Wednesday, June 26, 2013

Viruses in gut confer antibiotic resistance to bacteria

25 June 2013

Potential new target to thwart antibiotic resistance: Viruses in gut confer antibiotic resistance to bacteria

Bacteria in the gut that are under attack by antibiotics have allies no one had anticipated, a team of Wyss Institute scientists has found. Gut viruses that usually commandeer the bacteria, it turns out, enable them to survive the antibiotic onslaught, most likely by handing them genes that help them withstand the drug. What's more, the gut viruses, called bacteriophage or simply phage, deliver genes that help the bacteria to survive not just the antibiotic they've been exposed to, but other types of antibiotics as well, the scientists reported online June 9 in Nature. That suggests that phages in the gut may be partly responsible for the emergence of dangerous superbugs that withstand multiple antibiotics, and that drug targeting of phages could offer a potential new path to mitigate development of antibiotic resistance. "The results mean that the antibiotic-resistance situation is even more troubling than we thought," said senior author Jim Collins, Ph.D., a pioneer of synthetic biology and Core Faculty member at the Wyss Institute for Biologically Inspired Engineering, who is also the William F. Warren Distinguished Professor at Boston University, where he leads the Center of Synthetic Biology.

Today disease-causing bacteria have adapted to antibiotics faster than scientists can generate new drugs to kill them, creating a serious global public-health threat. Patients who are hospitalized with serious bacterial infections tend to have longer, more expensive hospital stays, and they are twice as likely to die as those infected with antibiotic-susceptible bacteria, according to the World Health Organization. In addition, because first-line drugs fail more often than before, more expensive therapies must be used, raising health-care costs. In the past, Collins and other scientists have probed the ways gut bacteria adapt to antibiotics, but they've focused on the bacteria themselves. But Collins and Sheetal Modi, Ph.D., the lead author of the study and a postdoctoral fellow in Collins' laboratory and at the Wyss Institute, knew that phage were also abundant in the gut, and that they were adept at ferrying genes from one bacterium to another. The researchers wondered whether treating mice with antibiotics led phage in the gut to pick up more drug-resistance genes, and if so, whether that made gut bacteria stronger. They gave mice either ciprofloxacin or ampicillin -- two commonly prescribed antibiotics. After eight weeks, they harvested all the viruses in the mice's feces, and identified the viral genes present by comparing them with a large database of known genes. They found that the phages from antibiotic-treated mice carried significantly higher numbers of bacterial drug-resistance genes than they would have carried by chance. What's more, phage from ampicillin-treated mice carried more genes that help bacteria fight off ampicillin and related penicillin-like drugs, while phage from ciprofloxacin-treated mice carried more genes that help them fight off ciprofloxacin and related drugs. "When we treat mice with certain classes of drugs, we see enrichment of resistance genes to those drug classes," Modi said. The phage did more than harbor drug-resistance genes. They could also transfer them back to gut bacteria -- a necessary step in conferring drug resistance. The researchers demonstrated this by isolating phage from either antibiotic-treated mice or untreated mice, then adding those phage to gut bacteria from untreated mice.

Phage from ampicillin-treated mice tripled the amount of ampicillin resistance, while phage from ciprofloxacin-treated mice doubled the amount of ciprofloxacin resistance. That was bad enough, but the scientists also found signs that the phage could do yet more to foster antibiotic resistance. That's because gut phage from mice treated with one drug carried high levels of genes that confer resistance to different drugs, which means that the phage could serve as backup when bacteria must find ways to withstand a variety of antibiotics. "With antibiotic treatment, the microbiome has a means to protect itself by expanding the antibiotic resistance reservoir, enabling bugs to come back to be potentially stronger and more resistant than before," Collins said. "Antibiotic resistance is as pressing a global health problem as they come, and to fight it, it's critical to understand it," said Don Ingber, M.D., Ph.D., Wyss Institute Founding Director. "Jim's novel findings offer a previously unknown way to approach this problem -- by targeting the phage that live in our intestine, rather than the pathogens themselves."

Science Daily
June 25, 2013

Original web page at Science Daily

Tuesday, June 25, 2013

Accelerating Lyme Disease Diagnostics


Accelerating Lyme Disease Diagnostics

New measurement technologies bring hope for early-stage detection
Department: Government & Policy
The Lyme spirochete bacterial is spread from ticks to human and is the cause of Lyme disease.
B. burgdorferi, spirochetal bacteria that cause Lyme disease, are difficult to detect directly because only a small number are present in a patient’s blood. The average length of the bacterium is 20–30 µm.
Credit: Janice Haney Carr/CDC

When Tracy Lambeth woke up one day with extreme back pain, she brushed it off as a pulled muscle. But after several weeks, the pain did not go away. She was tested for Lyme disease, even though she did not have a bull’s-eye rash—a common sign of the illness—or any recollection of a tick biting her. The results were negative. Tracy, then 26 and living in Pennsylvania, was told she had fibromyalgia and was sent home without any treatment.

One-and-a-half years later, Tracy was bitten by a tick and developed a bull’s-eye rash on the back of her knee. She was hospitalized for four days. “We think I had the bacteria in my system, and this next tick bite just made everything worse,” she says.

Read rest of story:

Friday, June 21, 2013

Congressional investigation of the CDC, IDSA and ALDF?

The U.S. Senate: Calling for a Congressional investigation of the CDC, IDSA and ALDF

The U.S. Senate: Calling for a Congressional investigation of the CDC, IDSA and ALDF

Sign the petition:
Petitioning The U.S. Senate 

This petition will be delivered to:
  • The U.S. Senate
  • The U.S. House of Representatives
  • The Governor of NH
  • The NH State Senate
  • The NH State House
  • The U.S. Senate
  • United States Senator for Connecticut
  • Senator Richard Blumenthal
  • Comptroller General of the United States
  • Gene L. Dodaro
  • Congressional Relations GAO
  • Katherine Siggerud
We are experiencing a health crisis here in New Hampshire and across the country with the growing epidemic of Lyme disease. A number of legislators have personally been affected and have introduced legislation to address this problem. Here are just a few recent examples.

We are experiencing a health crisis here in New Hampshire and across the country with the growing epidemic of Lyme disease. A number of legislators have personally been affected and have introduced legislation to address this problem. Here are just a few recent examples.

Representative David Linsky: “The occurrence of Lyme disease has reached near epidemic proportions in Massachusetts. Virtually every family in Massachusetts has been affected by Lyme disease in some way. Lyme disease is a public health crisis in the Commonwealth.” Read more…

 Connecticut, Rhode Island, New York
Senator Richard Blumenthal: "Today for me culminates more than a decade of work and probably a decade more, because I've seen firsthand the devastating, absolutely unacceptable damage done by Lyme disease to individual human beings, Connecticut children and residents whose lives have been changed forever as a result of Lyme disease” Read more….

New Jersey, Pennsylvania
Congressman Chris Smith: "It seems everywhere I go, someone comes up to me to talk about how Lyme disease has severely impacted their lives or someone they know," Read more…

Virginia Governor’s Task Force Chair Michael P Farris, Esq: "Doctors here in Virginia are committing malpractice by saying the ELISA test is sufficient." Read more…

Sign the petition:

Taking back the Lyme research agenda, one project at a time

TOUCHED BY LYME: Taking back the Lyme research agenda, one project at a time
13th June 2013

How the Lyme community stepped up--with donations big and small--to buy a sophisticated microscope and support the groundbreaking research of Dr. Eva Sapi. (Pssst: still time to donate!)

More than 20 years of government-funded Lyme disease research hasn’t brought us any closer to a cure. Basically, the same folks who created the IDSA Lyme guidelines–which systematically deny care to thousands of Lyme patients every year–also have a lock on government-funded Lyme research money. This results in dead-end projects that waste time and money and do nothing to help suffering Lyme patients.

That’s why we support the trailblazing Lyme research of Dr. Eva Sapi, of the University of New Haven. She has made great strides towards solving the puzzle of Lyme disease—developing new culture techniques, investigating how antibiotics affect all forms of the Lyme bacteria, and examining the role of biofilms in Lyme. She is committed to finding out why the Lyme bacteria can persist in the face of antibiotic treatment, which is critical to finding a cure.

A few months ago, we found out she needed a new piece of equipment–an atomic force microscope–to take her research to the next level. This sophisticated instrument can magnify the Lyme spirochete 1000 times more than standard microscopes, allowing her to observe many live forms of Borrelia under many different conditions.

One of these babies costs about $110,000. We contacted some of our donors privately, asking if they wanted to help out. Some generous people answered that call, and by April,  we needed only $20,000 more to complete the purchase.

On May 1, in honor of Lyme Awareness Month, we launched a fundraising page, asking members of the Lyme community to help us close the gap and buy the microscope. Via donations big and small, the needed $20,000 was raised in three days!

Since people still wanted to donate, we pledged that all additional funds raised via that page will go towards Dr. Sapi’s first research project with the new microscope, aimed at unlocking the secrets of Lyme biofilms. More people donated, bringing the current amount raised on the page to more than $30,000.

You guys are great!

The fundraising page will be active until the end of June. I repeat, after the purchase of the microscope, all additional money raised via this channel will go to support Dr. Sapi’s research.

Think we can hit $40,000?

Click here to go to the fundraising page.

TOUCHED BY LYME is written by Dorothy Kupcha Leland,’s VP for Education and Outreach. Contact her at

Monday, June 17, 2013

IVIG for Peripheral Neuropathy

I saw this note on the California Lyme listserv today:
A listserv member brought this to the attention of the group today. 
Intravenous immunoglobulin therapy helped all of the lyme patients with neuropathy 
after 6 months of one treatment per month. You may be put off by the 
starting premise of the study -- that their symptoms were part of post-lyme 
treatment syndrome -- but the conclusion seemed to be that they still had Lyme or 
would not have benefited from the IVIG therapy. 

Source: DGNews 
Immunoglobulin Therapy Effective for Neuropathy in Patients With 
Post-Treatment Lyme Syndrome
Presented at AAN

By Andrew Wilner, MD

SEATTLE, Wash -- May 2, 2009 -- Intravenous immunoglobulin (IVIG) therapy 
may improve neuropathic symptoms in patients with post-treatment Lyme 
syndrome, researchers stated here on April 28 at the American Academy of 
Neurology (AAN) 61st Annual Meeting.

A significant number of patients who had Lyme disease will continue to 
have lingering symptoms referred to as post-treatment Lyme syndrome, 
according to presenter Amiram Katz, MD, Lambert Professional Center, Orange, 
Connecticut. Similar symptoms are seen in patients who have received the Lymerix 

The study included 30 patients seen by Dr. Katz (13 females, 17 males; 
mean age 48.2 years) who complained of neuropathic pain.

Of the patients, 22 had a history of Lyme disease and 8 patients had 
received the Lymerix vaccine. All patients had antibodies to outer surface 
protein A (anti-OspA) and persistent symptoms despite at least 1 course of 

Twenty-four patients had electrodiagnostic studies, but there was a poor 
correlation between electrodiagnostic and nerve biopsy results.

Four patients with abnormal electrodiagnostic studies had normal epidermal 
nerve fibre density on nerve biopsy, while 10 patients with normal 
electrodiagnostic studies had abnormal epidermal nerve fibre density on nerve 
biopsy. Three patients had inflammatory changes around the nerve endings on 
skin biopsy.

All patients were treated with IVIG 2 g/kg per month for at least 6 months.

After IVIG treatment, all patients had improvement of their neurological 
examination with respect to their sensation, Achilles reflex, and Romberg 
test. Several patients also showed improvement in the number of nerve fibres 
on repeat nerve biopsy after treatment. There was no placebo group.

"The diagnosis of chronic Lyme disease is not widely accepted, yet these 
patients have symptoms and nerve biopsies that respond to IVIG treatment, 
legitimising their complaints," concluded Dr. Katz.

[Presentation title: Diminished Epidermal Nerve Fiber Density in Patients 
With Antibodies to Outer Surface Protein A (OspA) of B. burgdorferi 
Improves with Intravenous Immunoglobulin Therapy. Abstract P02.021]

Friday, June 14, 2013

Lots of articles on Lyme research

Here's good reading for a week!

Type in any keyword for other research on illnesses.

Issues of Concern for Lyme Patients and the General Public

This is an exposé published in the Poughkeepsie Journal addressing the issues chronic Lyme disease (CLD) patients as well as the general public are facing:

problems with patient care
treating co-infections
lack of screening for babesia in the blood banks

This reporter is very bright, she gets it, she writes well, and is willing to do more. She spoke with Pat Smith, Drs. Fallon, Horowitz, Liegner, Pam Weintraub, Congressman Gibson, Assemblyman Miller and many others including Baker and Wormser.

All you have to do is look at the video, and read her stories below to
see how clever she is at exposing the problems with the "system".

1. Video Interview of Chronic Lyme Patients|tvideo2|article

2. Exposé About the Seriousness and Underreporting in NYS as started in
CT and spread to WI - Where next?

3. About the seriousness of Babesia|mostview

FDA Comes to Grips with Fecal Transplants

Efforts are under way to standardize fecal transplants, which helps re-establish healthy microbe populations in the guts of patients

By Beth Mole and Nature magazine

The brown slurry is piped through tubes into the top of the human body — or the bottom. It can even come in pill form. For years, doctors have been transferring feces into ill people’s intestines to replace resident microbes with a fresh batch. The procedure is often a therapeutic success, but protocols for it vary wildly. As it steadily grows more popular, regulators are now working to define what a standard fecal transplant should be, and how to deliver one safely.

Read the rest of the story:

- Posted using BlogPress from my iPad

Sunday, June 9, 2013

Personal update 5-23-13

Here's my personal update for the day. It's kind of a downer. But it's the best I can muster, and it's honest.

There is a lot I didn't say that is some background. For example, earlier in the month I was in the hospital because it looked as though my port was infected. The first we did a blood culture from two locations -- the port and then a peripheral vein. The vein came back negative the the port came back positive, for Staphylococcus aureus.

Then the surgeon looked at the port that he himself had installed in my chest, and his opinion was that it should come out. The reasoning is that if the port was infected it could have infected the heart, and it could mess up a heart valve. That would require heart surgery to replace a bad valve. So he removed it and sowed me back up.

Now that the port was out of the picture, we did another culture and found that the bacteria had moved into the circulatory system in general. So that meant I had a legitimate case of sepsis. Not good. Once you have bacteria in your blood then infection can go anywhere, and set up camp. Luckily the infection did not have resistance to all antibiotics. It was sensitive to three different ones. That means, that it could be killed off by at least three kinds of antibiotics that are easily available. The doctor chose to put me on vancomycin. I was in the hospital for three days on a steady drip of that.

My stay in the hospital was generally traumatic. I was quarantined in my room, not allowed to walk around the hospital. People were not to touch me, while we waited for the results from the lab. That was because they were concerned that I might have MRSA (Methicillin Resistant Staphylococcus Aureus). I was concerned about that possibility, of course. How ironic would it be to have been treating bacteria all these years (almost 10 years), only to get an incidental infection in a port that could've killed me.

I know that these kinds of unexpected complications that can result from having a "central line" for long-term treatment of Lyme disease gave me pause for thought before I decided to get one. But weighing the pluses and minuses of having a port, considering that I would be embarking on maybe a multi – year regimen of daily IVs, the plusses prevailed. There's always the chance that a central line can become infected. However, I was long overdue for heavy-duty antibiotic treatment, having been messing around with oral antibiotics and supplements for close to five years already, and showing little improvement. In fact I was continuing to decline.

Then also, there is the argument by the conservative medical establishment that doing antibiotics for that long can cause Lyme patients' bodies to become more resistant to antibiotics. The argument goes — and it's a reasonable argument — that bacteria of all kinds are very intelligent, and can change their molecular structure in order to survive the onslaught of high quantities and and/or long durations of IV antibiotics. This is especially true of the bacterium responsible for Lyme disease (Borellia). This bacterium has many more genes than does the syphilis bacteria, and we know that syphilis is a mighty adversary. Also, like syphilis, Borrelia is a "great imitator." Estimates are that it can cause a human body to develop symptoms that appear clinically like more than 200 different diseases that have nothing to do with Lyme disease, per se. But, I digress.

Why should doctors who are worried about the development of resistant strains of bacteria pick on Lyme patients and their doctors? There are other examples of syndromes and diseases for which doctors prescribe long-term use of antibiotics. Teenagers with acne and folks with diabetic wounds that won't heal are two good examples. My understanding is that the conservative medical establishment does not call those doctors before a medical review board, put them on probation, or take away their license to practice.

What I have read is that the biggest culprit in the development of resistant strains of bacteria (sometimes called "super bugs") is the policy of blanket administration of antibiotics to livestock, such as cattle. The argument goes that when we ingest the meat, we also are "taking" the antibiotics. We also drink the water that comes out of the water table that the antibiotics have seeped down into, from these highly potent cattleyards. So we humans are ingesting antibiotics just as if we were taking pills prescribed by a doctor. Collectively, bacteria that are just sitting around in our bodies are actively adapting themselves to live in this new environment of basically antibiotic soup anyway. Why deprive people who are terribly sick, and often have been sick for many years, a pass on this particular issue? Could it be that insurance companies don't want to pay for the high cost of antibiotic therapy for its customers who have been diagnosed with Lyme disease? If we want to get serious about reducing the development of superbugs, why not look at much larger contributors to the problem, such as the ubiquitous use of anti-microbial hand cleaners (those antibiotics go straight into the water treatment plants and often come back to us in the form of drinking water), and the overuse of antibiotics for farm raised animals (including farm-raised fish)?

A free online movie about Lyme disease

Here's a flick I didn't know existed. It's about a half hour long about a skier, a young woman who was struck down by Lyme disease and how she recovered with the help of a Lyme doctor on the East Coast, Dr. Cameron, from Mount Kisco, New York.

Angeli VanLaanen is a freestyle skiier from Bellingham Washington who after being sidelined with Lyme disease now has plans of competing in the Sochi 2014 Winter Olympics. She never got real sick, but it's still good. 

Angeli made a very inspirational documentary about her life and Lyme disease that can be watched online:

Obamacare Explained: A Guide for Californians

From KQED Public Media for Northern CA

Starting January 1, 2014, most Americans will be required to have health insurance or pay a fine. It's part of President Obama's Affordable Care Act. Whether you love it, hate it or are just plain confused, the ACA is the law of the land. The thousand-page law covers a lot of ground and figuring out what part of it has to do with you can be a challenge.
Don't panic.
Read the site!

Ozone therapy & Parkinsons

This sounds like a promising approach. I had not heard about this before, at least not specific to Parkinson's treatments.

If you know anything about this, please post a comment in response to this post.

Sunday, June 2, 2013

Hepatitis A from Costco Frozen Berries?

Health officials have linked frozen berries from a Fairview producer sold in Costco ( to a hepatitis A outbreak in five states.

At least 30 people have become ill since April 29, according to statements Friday from state and federal officials. The cases are spread among Arizona, California, Colorado, Nevada and New Mexico. No patients have been identified in Oregon.

Food safety sleuths traced the outbreak to frozen berries produced by Townsend Farms in Fairview. The Food and Drug Administration said that 11 of 17 people interviewed so far consumed Townsend Farms ( Anti-Oxidant Blend, which contains cherries, blueberries, pomegranate seeds,


Keep up with recalls, food safety news (


The Oregonian's database of food recall news and updated federal warnings about food safety.

Recall news, warnings » (